AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
With a market cap of 358.42B, AbbVie(ABBV) trades at $202.66. The stock has a price-to-earnings ratio of 100.85 and currently yields dividends of 3.3%.
On 2026-05-08, AbbVie(ABBV) stock moved within a range of $202.06 to $207.00. With shares now at $202.66, the stock is trading +0.3% above its intraday low and -2.1% below the session's peak.
Trading activity shows a volume of 6.68M, compared to an average daily volume of 7.15M.
The stock's 52-week range extends from a low of $176.57 to a high of $244.81.
The stock's 52-week range extends from a low of $176.57 to a high of $244.81.
ABBV News
In late April and early May 2026, AbbVie reported first‑quarter revenue of US$15.00 billion alongside a year-on-year drop in net income to US$695 million, while...
Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Di...
There are plenty of dividend stocks on equity markets. Few are more secure than Dividend Kings, a group of corporations that have raised their payouts annually...
Analyst ratings
74%
of 34 ratingsMore ABBV News
Technology This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout Licensing Biotech stock Avalo Therapeutics (AVTX) skyroc...
AbbVie (NYSE:ABBV) is expanding access to SKYRIZI for ulcerative colitis patients in Canada through new formulary listings and positive reimbursement recommenda...
Key Points AbbVie is a Dividend King that has proven its ability to adapt. Realty Income is the ultimate monthly income play. 10 stocks we like better than R...
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, AbbVie Inc (Symbol: ABBV) has taken over the #77 sp...
Key Points The stocks listed here pay more than 3% in dividends. These payouts are high, but they are safe and are backed by strong financials. By diversifyi...
AbbVie (ABBV) announced the presentation of new data across its gastroenterology portfolio at the 2026 Digestive Disease Week, or DDW, Annual Meeting, May 2-5 i...
Key Points AbbVie posted strong first-quarter results. The company's two biggest growth drivers continue to exceed expectations. AbbVie's overall business lo...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.